Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q2 2025 · 10-Q
Revenue$178.24K$178.24K+4,306.4% vs Q2 2024 Net Income-$1.23M-$1.23MN/M vs Q2 2024 EPS Diluted-$0.07-$0.07N/M vs Q2 2024 Operating Income-$1,413,920N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-793.3%+33059.7 pt vs Q2 2024
Net margin-692.0%+29814.7 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end